

Medical Officer Labeling Review
Division of Gastroenterology and Inborn Error Products

NDA#: 22523/S-004

Sponsor: Janssen Research & Development, LLC

Drug: Pancreaze (pancrelipase)

Drug Classes: Pancreatic Enzyme Product (PEP)

Dose and Form: 2,600 lipase unit capsule / oral

Proposed Indication: The treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis and other conditions

Date Review Completed: February 26, 2014

Clinical Reviewer: Marjorie F. Dannis, M.D.

Team Leader: Anil Rajpal, M.D.

The mutually agreed (between Janssen Research & Development and FDA) upon labeling changes which represent the new dosage strength of 2,600 lipase units are shown below:

Labeling - Package Insert

A. Highlights of Prescribing Dosage Section - Infants (up to 12 months)

Revise first bullet to read as follows:

“Infants may be given **2,600** lipase units per 120 mL of formula or per breast-feeding”.

B. Full Prescribing Information (Dosage Section 2.1)

1. Paragraph 3 should be revised as follows:

Dosage recommendations for pancreatic enzyme replacement therapy were published following the Cystic Fibrosis Foundation Consensus Conferences.^{1,2,3} PANCREAZE should be administered in a manner consistent with the recommendations of the Conferences provided in the following paragraphs **with one exception. The Conferences recommend doses of 2,000 to 4,000 lipase units in infants up to 12 months. PANCREAZE is available in a 2,600 lipase unit capsule. The recommended dose of PANCREAZE in infants up to 12 months is 2,600 lipase units per 120 mL of formula or per breast-feeding.** Patients may be dosed on a fat ingestion-based or actual body weight-based dosing scheme.

2. Dosage - Infants (up to 12 months): Revise the usual dosage to read as follows:

Infants (up to 12 months)

Infants may be given **2,600 lipase units** per 120 mL of formula or per breast-feeding. Do not mix PANCREAZE capsule contents directly into formula or breast milk prior to administration [see *Dosage and Administration (2.2)*]

C. Full Prescribing Information (Administration Section 2.2)

Change dose listed for infants up to 12 months of age from (b) (4) lipase units to **“2,600 lipase units per 120 mL of formula or per breast-feeding”**. The paragraph should read as follows:

Infants (up to 12 months)

PANCREAZE should be administered to infants immediately prior to each feeding, using a dosage of **2,600 lipase** units per 120 mL of formula or per breast-feeding (i.e., **one capsule with 2,600 USP units of lipase**). Contents of the capsule may be sprinkled on small amounts of acidic soft food with a pH of 4.5 or less (e.g., applesauce) and given to the infant within 15 minutes. Contents of the capsule may also be administered directly to the mouth. Administration should be followed by breast milk or formula. Contents of the capsule **should not** be mixed directly into formula or breast milk as this may diminish efficacy. Care should be taken to ensure that PANCREAZE is not crushed or chewed or retained in the mouth, to avoid irritation of the oral mucosa.

Additional Comments

PeRC was convened on February 12, 2014 to discuss this supplement. It was their conclusion that Janssen Research & Development had satisfied the post-marketing requirement that an age appropriate formulation be developed for the youngest patients. DGIEP is in agreement with PERC that this PMR has been satisfied. In addition, DGIEP agrees with the labeling changes as presented above.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARJORIE F DANNIS
02/26/2014

ANIL K RAJPAL
02/26/2014